Daclizumab: DECIDE trial update


REPORT FROM ECTRIMS – BARCELONA, SPAIN – OCTOBER 7-10, 2015 – DECIDE is the second phase III trial evaluating daclizumab, an anti-CD25 monoclonal antibody that modulates IL-2 signalling. Primary results were presented at the American Academy of Neurology annual meeting (Kappos et al. AAN 2015; abstract S4.003) but are not yet published. Subjects (mean age 36 years) were randomized to subcutaneous daclizumab 150 mg q4weeks or intramuscular interferon-beta-1a for 96-144 weeks.

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page